Fluoptics Opens US Office
To market and sell its offerings for preclinical in vivo fluorescence imaging, Grenoble, France-based Fluoptics has opened an office in Cambridge, Mass. The company develops solutions that combine a nonradioactive fluorescent tracer targeting cancer cells with its Fluobeam real-time optical imaging system. The device, due to enter clinical trials this year in Europe, is available to the preclinical research market. “We will now work on accelerating the distribution of our preclinical instruments in the US and Canada directly or through key partnerships,” said Odile Allard, CEO of Fluoptics. The technology will illuminate cancer cells in real time during surgery.
LATEST NEWS
- Exail Signs LLNL Contract, Partners with Eelume
Apr 26, 2024
- Menlo Moves U.S. HQ: Week in Brief: 4/26/2024
Apr 26, 2024
- Optofluidics Platform Keys Label-, Amplification-Free Rapid Diagnostic Tool
Apr 25, 2024
- DUV Lasers Made with Nonlinear Crystals Enhance Lithography Performance
Apr 25, 2024
- Teledyne e2v, Airy3D Collaborate on 3D Vision Solutions
Apr 24, 2024
- One-Step Hologram Generation Speeds 3D Display Creation
Apr 24, 2024
- Innovation Award Winners for Laser Technology Honored in Aachen
Apr 23, 2024
- Intech 2024: AI Arrives on the Shop Floor
Apr 22, 2024